Developments in Parasitic Disease Treatment Market Outlook: Ken Research


In modern times the medical field is constantly innovating to provide solutions for a variety of diseases. While there is no vaccine for parasitic diseases there is medication available today that can help people tackle the problem. Parasitic infections can usually be treated with anti parasitic drugs. Such drugs are undergoing extensive research today.

Many new projects are being explored around the world. Advances in science especially in the field of parasite genomics and its attendant technology have opened up possibilities for new drugs in common diseases like malaria.

  • Many researchers are taking steps in the direction of malaria eradication. Antifolate drugs in malaria are experiencing resurgence with the development of Lapdap (chlorproguanil-dapsone) nearing completion and an active programme devoted to the Triazine WR99210. However, the progress of malaria eradication is threatened by drug resistance and hence, medical research is also attempting to control the transmission of parasitic diseases. Two recently conducted studies characterize Plasmodium falciparum PKG inhibitors and Hexahydroquinolines as anti malarial compounds that could block transmission and help mitigate the risk of parasite escape via drug resistance.
  • The University of California San Diego has recently launched a new center for anti-parasitic drug discovery and development.
  • Along with this many contract research organizations (CROs) that provide support to pharmaceutical, biotechnical and medical device industries in the form of research services are also active in parasitic research. Laboratory Corporation of America Holdings (Covance), IQVIA and Syneos Health are all American clinical research organizations which are notable in this respect and are considered the best global contract research organizations.

According to the study “Parasitic Diseases Global Clinical Trials H1 2018” suggests that agencies are assisting in global efforts in this direction especially towards tackling malaria. International organizations such as WHO have begun aiding drug companies and related projects. They have been supported by economic agencies who state that unhealthy countries are condemned to slow growth. Initiatives such as Medicines for Malaria Venture are a result of such cooperation. A global trend has also been noticed that CROs have begun coordinating with government agencies and nonprofit organizations.

Renowned companies like GlaxoSmithKline plc, which is the UK’s largest drug maker, and Swiss Novartis AG are contributing to research funds that are global efforts and aim to combat malaria led by the Bill and Melinda Gates Foundation. Such research funds are receiving widespread support.

The current global trend reveals that parasitic diseases are not only furthering medical research but are raising awareness among people about just how lethal common parasitic disease like malaria can be. Such diseases are being tackled with medication but continuous and relentless efforts have begun to pay off, visible by various recent discoveries made. Strong Individual drugs have now been developed for malaria. These drugs are believed to be effective not only because of their increased vigor but also because of their characteristic to prevent further transmission of the disease. Even educational research institutions have contributed along with CROs. The latter’s cooperation with other agencies and global monetary funds raised in interest of public welfare clearly indicate developments in parasitic disease treatment with malaria being at its forefront.

To know more, click on the link below:

Contact Us:

Ken Research

Ankur Gupta, Head Marketing & Communications



Comments are closed.